US FDA approves KEYTRUDA from Merck for adults with relapsed or refractory cHL EP News Bureau Oct 15, 2020 KEYTRUDA is the first anti-PD-1 therapy approved for adult patients with relapsed or refractory cHL after frontline therapy
